Compare ADMA Biologics Inc (ADMA) vs FMC Corp (FMC) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

FMC Corporation trades at $11.59, up 2.11% today, but remains in a bearish technical trend. The company reported a net loss of -$2.24 billion in 2025 with negative margins, though recent strategic moves include a $400 million minority investment from Tessenderlo Group and asset sales to reduce debt. Analyst consensus is mixed with a $17.00 price target, suggesting potential upside from current levels.

The outlook hinges on successful debt reduction and operational turnaround. Investment opportunity exists if cost-cutting and partnerships restore profitability, but risks include persistent revenue declines, high leverage, and competitive pressures in the agricultural sciences sector. Execution on strategic initiatives is critical for recovery.